A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication

Status unconfirmed · Phase 4

Conditions studied: HIV-1, HIV Infections

In brief

The investigators seek to determine whether Virco®TYPE HIV-1 provides benefits equivalent to those provided by local expert review. The investigators propose that clinic patients of the Ruth M. Rothstein CORE Center who are having genotypic testing performed will be randomized in a 1:1 fashion to local expert review and to Virco®TYPE HIV-1. Results of either method will be shared with primary HIV care providers. Patient outcomes will be reviewed at a time point equal to or greater than 2 months and 6 months following the change in antiretroviral medications following the testing

Key facts

Study ID

NCT00840762

Run by

Ruth M. Rothstein CORE Center

People needed

756

Starts

2009-03-01

Expected to finish

2012-07-01

Last updated by the study team

2010-01-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV resistance testing that demonstrates resistance to at least one drug
• Patients of the CORE Center, Chicago Illinois

You may not qualify if…

• Wild type HIV on resistance testing or less than or equal to one active antiretroviral medication

Where it is running

• The Ruth M. Rothstein CORE Center — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.